The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 765K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

12 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
11
Evaluation of known and novel inhibitors of Orai1-mediated store operated CaEBI
The University of Queensland
3
Discovery of 7-azaindole derivatives as potent Orai inhibitors showing efficacy in a preclinical model of asthma.EBI
RhôNe-Poulenc Rorer
1
Discovery of selective Orai channel blockers bearing an indazole or a pyrazole scaffold.EBI
Harvard Medical School
46
Review of Transient Receptor Potential Canonical (TRPC5) Channel Modulators and Diseases.EBI
University of Nebraska Medical Center
25
An SAR study of hydroxy-trifluoromethylpyrazolines as inhibitors of Orai1-mediated store operated CaEBI
University of Auckland
658
CD73 COMPOUNDSBDB
Gilead Sciences
69
Compounds and methods for inhibiting JAKBDB
Dizal (Jiangsu) Pharmaceutical
14
Method of treating COVID-19BDB
Pfizer
17
Design, synthesis, and X-ray crystal structures of 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors.BDB
Duquesne University
25
Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors.BDB
Sunesis Pharmaceuticals
30
Inhibitors of the tyrosine kinase EphB4. Part 1: Structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines.BDB
AstraZeneca